After the Serum Institute of Life Sciences raised its stake in Biocon Biologics with an additional $150 million equity investment, Serum Institute of India (SII) CEO Adar Poonawalla said the alliance with Biocon Biologics is not limited to COVID-19 vaccines. "Will look at the manufacturing of vaccines beyond COVID-19," he told CNBC-TV18. Poonawalla said he was optimistic about this business.